In fact, as Gesualdo et al. [19] reported, in the post-TREAT era, investigators in the MONITOR-CKD5 study claimed to have a theoretical target Hb range for patients with (lower target) and without (higher target) such risk factors as hypertension, cardiovascular disease, history of stroke, diabetes, prior cancer, or being elderly. The gene discussed is GSTM1; the disease is stroke disorder.